Silver Book Fact

Potential savings from shingles vaccine

Use of the shingles vaccine in immunocompetent adults ages 60 and older could save between $82 and $103 million in healthcare costs associated with the diagnosis and treatment of shingles, post-herpetic neuralgia, and other complications.

Pellesier, James M., Marc Brisson, and Myron J. Levin. Evaluation of the Cost-Effectiveness in the United States of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. Vaccine. 2007; 25(49): 8326-37. http://www.ncbi.nlm.nih.gov/pubmed/17980938

Reference

Title
Evaluation of the Cost-Effectiveness in the United States of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Publication
Vaccine
Publication Date
2007
Authors
Pellesier, James M., Marc Brisson, and Myron J. Levin
Volume & Issue
Volume 25, Issue 49
Pages
8326-37
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • New antibacterial agents between 1983 and 2012
    Total number of new antibacterial agents is in decline  
  • Savings from flu vaccine
    Vaccination for influenza resulted in an average annual cost savings of $13.66 per healthy working adult vaccinated.  
  • Infection control program reduced hospital-acquired HAIs by > 1/3
    A multimodal infection control program reduced the rate of hospital-acquired HAIs by more than 1/3 and improved quality of care and patient outcomes.  
  • Pertussis vaccination reduced global cases
    Vaccination helped reduce global pertussis (whooping cough) cases from 3 million per year to less 250,000.  
  • Significant savings from zoster vaccine
    In a cost-effectiveness analysis, investigators estimated the zoster vaccine cost $44,000 per quality-adjusted life year saved for a 70-year-old woman.